Conference Reports

By Eric Ramos

MADRID, Spain -- October 13, 2019 -- A head-to-head trial comparing risankizumab (Skyrizi) with oral fumaric acid esters (FAE) for treatment-naïve patients with moderate-to-severe plaque psoriasis has demonstrated the superiority of risankizumab for all studied efficacy...

By Brian Hoyle

CHICAGO -- September 18, 2019 -- The likelihood of children with psoriasis having a higher systemic exposure to crisaborole than adults after topical application is low, according to a study presented here at the 2019 Annual Meeting of the American College of Clinical...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- In patients with moderate-to-severe psoriasis, risankizumab shows superior efficacy to ustekinumab after 52 weeks of treatment, according to an integrated analysis of the phase 3 UltlMMa-1 and UltlMMa-2 trials presented here at...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Certolizumab offers a durable long-term response to plaque psoriasis over 96 weeks, according to an open-label extension of the phase 3 CIMPASI-1 and CIMPASI-2 trials presented here at the 2019 Annual Meeting of the American...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Bimekizumab, a selective and potent inhibitor of interleukin (IL)-17A and IL-17F, shows rapid, effective, and safe results with long-term, subcutaneous dosing every 4 weeks, according to a study presented here at the 2019 Annual...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Continuous risankizumab, an interleukin (IL)-23 inhibitor, is safe and superior to adalimumab therapy for treatment of patients with moderate-to-severe psoriasis, as is switching from adalimumab to risankizumab, according to...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Patients with moderate-to-severe psoriasis maintain a long-term 75% reduction in Psoriasis Activity and Severity Index score (PASI75) with secukinumab, an interleukin 17A (IL-17A) monoclonal antibody, according to a study...

By Jenny Powers

PARIS -- September 18, 2018 -- Adding methotrexate to adalimumab increased the response in patients with psoriasis who demonstrated a previous suboptimal response to adalimumab monotherapy, according to results of a single-arm, open-label, longitudinal study of 46 patients...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab provided significant improvements to the Dermatology Life Quality Index (DLQI) that were sustained up to 64 weeks in patients with moderate-to-severe psoriasis, according to results from a post hoc pooled analysis of data from...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab is highly effective in patients with moderate to severe plaque psoriasis regardless of whether they had received prior biologic therapy, according to findings from a post hoc pooled analysis of data from the reSURFACE-1 and...

Pages